The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Black Diamond Therapeutics Inc shares valued at $1,400,556 were sold by Versant Venture Capital VI, L. on Aug 28 ’24. At $6.32 per share, Versant Venture Capital VI, L. sold 221,600 shares. The insider’s holdings dropped to 3,726,341 shares worth approximately $10.21 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, David Epstein purchased 50,000 shares, netting a total of over 310,000 in proceeds.
Before that, David Epstein had added 50,000 shares to its account. In a trade valued at $310,000, the Former Employee bought Black Diamond Therapeutics Inc shares for $6.20 each.
As published in their initiating research note from Raymond James on July 31, 2024, Black Diamond Therapeutics Inc [BDTX] has been an Outperform and the price target has been revised to $20. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid July. As of June 30, 2023, Stifel has increased its “Hold” rating to a “Buy” for BDTX. Earlier on June 28, 2023, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for BDTX stock which previously was a “a Neutral”.
Analyzing BDTX Stock Performance
During the last five days, there has been a drop of approximately -9.87%. Over the course of the year, Black Diamond Therapeutics Inc shares have dropped approximately -2.49%. Shares of the company reached a 52-week high of $7.66 on 05/06/24 and a 52-week low of $2.53 on 01/05/24. A 50-day SMA is recorded $4.48, while a 200-day SMA reached $4.89. Nevertheless, trading volume fell to 0.66 million shares from 0.67 million shares the previous day.
Support And Resistance Levels for Black Diamond Therapeutics Inc (BDTX)
According to the 24-hour chart, there is a support level at 2.68, which, if violated, would cause prices to drop to 2.63. In the upper region, resistance lies at 2.85. The next price resistance is at 2.96. RSI (Relative Strength Index) is 24.69 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.31, which suggests the price will decrease in the coming days. Percent R is at 99.36%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
